Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen.

Puntos clave

• The aim is to evaluate adherence to endocrine prevention using low-dose tamoxifen in women with atypical hyperplasia and lobular carcinoma in situ.
• Analyzed real-world data on medication adherence.
• Focused on women using low-dose tamoxifen.
• Monitored side effects and reasons for discontinuation.
• High adherence rates observed among women who started medication.
• Few patients discontinued treatment due to side effects.